Clarithromycin (CAS 81103-11-9) is a semi-synthetic macrolide antibiotic widely used in respiratory tract infections, skin infections and combination therapy for Helicobacter pylori eradication. As a derivative of erythromycin with improved acid stability and oral bioavailability, it offers robust activity against many Gram-positive and atypical pathogens.
Clarithromycin 81103-11-9 from TCS GROUP is supplied as a high-purity Active Pharmaceutical Ingredient (API) with tightly controlled impurities and comprehensive technical documentation. It is typically formulated into film-coated tablets, extended-release tablets or oral suspensions. The bitter taste and limited solubility of clarithromycin require careful excipient selection and coating design to ensure patient-friendly products.
In a modern antibacterial portfolio, clarithromycin is often complemented by other antibiotics to address different spectra and clinical needs. TCS INDUSTRIES LIMITED also supplies related antibacterial APIs, enabling customers to construct coherent product lines, for example:
- Clindamycin HCl 21462-39-5 – a lincosamide antibiotic widely used for serious anaerobic infections, bone infections and some skin/soft tissue infections.
- Chloramphenicol 56-75-7 – a broad-spectrum antibiotic suitable for selected systemic and topical/ophthalmic applications where benefits outweigh risks.
- The full antibacterial and API range can be browsed through the general Products overview on the TCS website.
From a formulation standpoint, clarithromycin developers must account for particle size, polymorphism, taste masking and dissolution in gastrointestinal media. Direct compression or wet granulation strategies are chosen depending on the target dosage form and release profile. TCS GROUP can support with typical guidance on compatible fillers, binders and coatings that have shown good performance with macrolide APIs.
By choosing Clarithromycin from TCS INDUSTRIES LIMITED, manufacturers gain a globally recognized antibiotic API supported by robust quality systems, documentation and a complementary antibacterial portfolio that helps streamline sourcing and project timelines.